Introduction
Feedback modulation is a central regulatory component in cellular information relay and decision making. [1] Aberrant processing of feedback circuits is often associated with disease phenotypes. [1] [2] [3] As a central regulator of nucleotide metabolism, ribonucleotide reductase (RNR) is a key drug target enzyme operating under tight feedback regulation. [4] [5] [6] [7] [8] [9] Recent biophysical and structural studies have shown that the feedback regulation of RNR imposed by the metabolite dATP-a ubiquitous mechanism in RNRs from yeast, mice, and humans-is coordinated with nucleotide-induced oligomerization of the RNR large subunit a. [8] [9] [10] [11] [12] [13] [14] However, neither the timescale of the self-assembly nor the identity of the transient intermediates involved in the assembly process have been interrogated in RNR from any species.
The human RNR (hRNR) holocomplex, composed of a and b subunits, catalyzes the rate-limiting conversion of nucleoside diphosphates (NDPs) to their deoxy forms (dNDPs) in the de novo biosynthesis pathway of dNTPs required for DNA replication and repair. [4] [5] [6] [7] [8] [9] hRNR activity is positively correlated with cancer cell growth, and suppressing hRNR activity is an effective strategy for repressing tumor survival, as demonstrated by a wealth of clinically used nucleoside antimetabolites. [9, 15, 16] The catalytic activity and substrate specificity of hRNR are tightly regulated allosterically. This allosteric regulation occurs exclusively on the a subunit. [6, 8] ATP or dATP binding at the allosteric activity (A) site on a respectively stimulates or suppresses overall RNR enzymatic activity. dNTP/ATP binding at the allosteric specificity (S) site determines the substrate specificity of a.
Mounting evidence indicates that allosteric regulation is strongly coupled to nucleotide-induced oligomeric state changes that occur solely on hRNR-a and do not require b. [8] [9] [10] [11] [12] [13] [14] The physiological relevance of such a oligomeric equilibria has also been demonstrated recently with the a-specific hexamerization-coupled inhibition induced by nucleotides of the antileukemic therapeutic clofarabine (ClF). [12] With dNTP/ATP natural allosteric effectors, some disagreement exists about whether higher-order oligomers can be assessed. [8] [9] [10] [11] [12] [13] [14] However, a large number of biochemical and structural reports have shown that the binding of the natural feedback allosteric inhibitor dATP at the A site induces a hexamerization of eukaryotic RNRs. [8] [9] [10] [11] [12] 14] In addition, nucleotide effector binding at the S site is believed to prime a to initiate substrate selection through a dimerization. [6, 8, 10, 11] The present study reports the development of the first readout directly reporting the two distinct hRNR-a oligomeric states. We applied this newly developed platform to monitor hRNR-a hexamerization events, triggered by the feedback regulator dATP, in real time (Figure 1 ).
Human ribonucleotide reductase (hRNR) is a target of nucleotide chemotherapeutics in clinical use. The nucleotide-induced oligomeric regulation of hRNR subunit a is increasingly being recognized as an innate and drug-relevant mechanism for enzyme activity modulation. In the presence of negative feedback inhibitor dATP and leukemia drug clofarabine nucleotides, hRNR-a assembles into catalytically inert hexameric complexes, whereas nucleotide effectors that govern substrate specificity typically trigger a-dimerization. Currently, both knowledge of and tools to interrogate the oligomeric assembly pathway of RNR in any species in real time are lacking. We therefore developed a fluorimetric assay that reliably reports on oligomeric state changes of a with high sensitivity. The oligomerizationdirected fluorescence quenching of hRNR-a, covalently labeled with two fluorophores, allows for direct readout of hRNR dimeric and hexameric states. We applied the newly developed platform to reveal the timescales of a self-assembly, driven by the feedback regulator dATP. This information is currently unavailable, despite the pharmaceutical relevance of hRNR oligomeric regulation.
Results and Discussion

Fluorescence assay development
We first focused on dATP-induced hexamerization as a readout, initially investigating the quenching of intrinsic tryptophan fluorescence as a hexamerization reporter. [17] No fluorescence change was observed upon dATP-induced a oligomerization, presumably because of the large number of Trp residues (12) on a. We thus undertook identification of a robust fluorophore labeling method with minimal perturbation to a oligomerization. The functionality of hRNR-a depends on the presence of essential Cys residues in the reduced (free thiol) state. [4] Some of these residues reside on the solvent-exposed flexible C-terminal tail of a. hRNR-a is also highly sensitive to oxidation, and the oxidized protein is prone to precipitation. These features rendered incompatible a number of site-specific chemical-and mutagenesis-based labeling strategies that have been used successfully with the bacterial RNRs. For instance, we found that the prolonged reaction time and additives used in native chemical ligation [18] unavoidably led to protein precipitation.
Previous work showed that N-terminal hexahistidine (His 6 )-tagged a hexamerizes in the presence of dATP or ClF di-and triphosphates [ClFD(T)P] in the same manner as the enzyme from which the His 6 tag has been removed. [11, 12] We thus anticipated that a fluorophore could be incorporated site-specifically by using ATTO dyes [19] that bind to the His 6 tag. However, because ATTO dye labeling of the His 6 tag is noncovalent, we observed dye dissociation under dilute reaction conditions. We also attempted to use a Lap tag, [20] which can be enzymatically modified, inducing covalent labeling of the Lap-tagged protein. However, the N-terminal Lap-tagged a failed to hexamerize upon treatment with hexamerization inducers. We also constructed and isolated catalytically functional a variants genetically encoded at the N-terminus with the commonly used protein tags: enhanced green fluorescent protein (eGFP), [21] monomeric red fluorescent protein (mRFP), [22] and HaloTag. [23] These fusion proteins also impeded hexamerization. Our labeling efforts highlighted the sensitivity of hRNR-a hexamerization to N-terminal perturbations, an observation consistent with the fact that the N-terminus provides the physical dimer interface within the trimer-of-dimers (a 2 ) 3 complex. [10, 12] We ultimately identified a non-intrusive labeling strategy by using small amounts of thiol-reactive dyes in the presence of the reducing agent dithiothreitol (DTT). We hypothesized that the presence of the reducing agent provided a reaction environment in which DTT maintained the solubility and functional integrity-specifically, the oligomerization capacity-of hRNRa. A 20 min incubation with either 5-iodoacetamidofluorescein (5-IAF), or tetramethylrhodamine-5-iodoacetamide dihydroiodide (5-TMRIA), resulted in 1.0 AE 0.2 and 0.9 AE 0.1 equiv, respectively, of covalent fluorophore labeling per polypeptide (Figure 2 A and B and Table S1 ). Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis suggested that, based on 66 % peptide coverage, labeling occurred primarily on three solvent-exposed catalytically non-essential Cys residues: Cys254, Cys662, and Cys779 ( Figure S1 ). Importantly, gel filtration analysis showed that both the fluorescein-labeled and the tetramethylrhodamine-labeled a (hereafter F-a and T-a) hexamerized as efficiently as unlabeled a in the presence of 20 mm dATP in the running buffer (Figures 2 C and S2 ). The activities of F-and T-a were not largely perturbed, maintaining 72 AE 2 % and 68 AE 8 %, respectively, of the activity of unlabeled a treated under otherwise identical conditions (Figure S3 A) . The capability of the labeled a to undergo a hexamerization suggests that our covalent labeling strategy was noninvasive and therefore suitable for modeling the hexamerization pathway. However, the observed partial loss in activity of the labeled a means that the calculated rates of oligomerization might differ slightly from those of the unlabeled protein. We further validated the also Table S1 and Figure S1 ). Note: peak splitting is a common spectral feature of TMR-labeled proteins (see, e.g., manuals from Life Technologies, Genaxxon BioScience, and AnaSpec). C) Labeled protein hexamerizes efficiently. Gel filtration analysis of F-a with and without dATP. a and g designate A280 and A495 traces, respectively (see also Figure S2 ). capacity of the labeled proteins to hexamerize by using the known hexamerization inducers ClFD(T)P ( Figure S2 ).
We next sought to identify the simplest and most reliable fluorimetric readout of a hexamerization. Fluorescent quenching in the presence of a 1:5 mixture of F-a (donor) and T-a (acceptor) was the most versatile and sensitive hexamerization reporter ( Figure 1 ). Under these conditions, saturating concentrations of all three hexamerization-inducers-dATP and ClFD(T)P-caused a 46-48 % drop in F intensity. Titration with dATP revealed a dose-dependent signal drop ( Figure 3 and S4 A). The half-maximal effective concentration (EC 50 ) of the dATP-driven a hexamerization was calculated to be 2.3 AE 0.3 mm (Figure 3 B ). Similar titrations with ClFD(T)P showed that a hexamerization was inducible at a concentration much lower than that of dATP (Figure 3 B) . Because the minimum protein concentration for reliable fluorescence readout was~180 nm, we fit the ClFD(T)P titration data to a tight-binding equation, [24] yielding K d values instead of EC 50 values. The resultant K d values of~185 AE 36 and 74 AE 19 nm, respectively, were within the range of the K i values deduced from inhibition assays. [11] Importantly, nucleotides such as substrate CDP and the clinically used substrate analogue suicide inactivator, gemcitabine diphosphate (F2CDP), which are incapable of altering the hRNR-a subunit quaternary structure, [9] did not induce an appreciable fluorescence change ( Figure S5 A and S5 B) . Controls in which F-a alone or unlabeled a in place of T-a ( Figure S5 C-D) was treated with inducers showed a < 1-3 % drop in donor intensity. These observations suggest that no fluorescein quenching occurred due to nucleotide binding or interaction with protein residues.
To confirm that the observed quenching was due to a fluorescence resonance energy transfer (FRET) process, we subtracted the donor fluorescein intensities obtained from the samples with F-a alone from the emission spectra of an F-and T-a mixture at 0 and 200 mm dATP. An increase in T-a-specific intensity promoted by dATP was observed, indicating the presence of FRET ( Figure S4 B and C).
hRNR-a is monomeric in the absence of any substrates and effectors, [8] [9] [10] [11] [12] [13] [14] and a wealth of evidence indicates that a alone can adopt a dimeric state. The a 2 dimeric state is induced upon effector binding at the S site, [6, [8] [9] [10] [11] [12] [13] [14] and dimerization is a prerequisite for adoption of the a 2 b 2 active state by the holoenzyme. [25] The a 2 quaternary state of hRNR-a (without b) has also been well-characterized by crystallography. [10] We were thus interested in the extent to which our fluorescence protocol could distinguish between a hexamerization and dimerization. We first took advantage of the previously characterized hRNR His 6 -D57N-a. [11] D57N-a is unresponsive to dATP-induced hexamerization-coupled inhibition. However, owing to dATP binding at the S site, this mutant is dimeric under saturating concentrations of dATP. [11, 26] His 6 -D57N-a was covalently labeled with either F or T (Figure S6 A) , resulting in 0.9 AE 0.11 and 0.9 AE 0.3 equivalents, respectively, of covalent dye labeling per polypeptide (Table S1 and Figure S6B ). Gel filtration analysis in the presence of dATP in the running buffer showed that the labeled proteins dimerized with effiencies similar to that of the unlabeled mutant ( Figure S2 E and S2 I). The specific activities of F-and T-D57N-a were 73 AE 8 % and 61 AE 2 % of the unlabeled D57N-a ( Figure S3 A) .
Compared with the 46-48 % drop in F intensity observed for dATP-induced wild-type (wt)-a hexamerization, dATP promoted 37 AE 3 % quenching when wt-a was replaced with mutant a under otherwise identical conditions. As a means for identifying a set of conditions in which the magnitudes of quenching resulting from dimerization and hexamerization are optimally different, the drop in the donor intensity at 520 nm was examined across various donor:acceptor ratios of F-:T-D57N-a (dimerization) and compared with the results obtained for F-:T-a (hexamerization; Figure S3 B) . The results showed that the fluorimetry sensitivity enabled the extent of quenching induced by a dimerization to be 10 AE 3 % lower than for a hexamerization. Notably, the degree of donor quenching gradually declined as the proportion of T-a with respect to F-a decreased. This observation additionally corroborated the presence of FRET ( Figure S4 B and C) . As the ratio of F-:T-a decreased beyond 1:1, the degree of quenching reached a plateau. A similar saturation effect was reported in previous FRET studies in which changes in the relative populations of donors to acceptors have little effect on FRET efficiency when the donor/acceptor ratio is < 1. [27] The allosteric activator ATP is also thought to induce a oligomerization independent of b, although the precise nature of the resulting oligomeric state remains unsettled. [8] [9] [10] [11] [12] [13] [14] However, initial attempts to examine the effects of ATP by using our new fluorescence assay revealed that the high (millimolar) ATP nucleotide concentrations required to induce a oligomerization quenched the fluorescein signal, even in the sample containing only F-a alone or in the presence of 5-IAF dye alone without a. Thus, the effects of ATP cannot be analyzed by this assay.
Stopped-flow fluorescence analyses
The successful development of a direct and sensitive fluorescence readout of the dATP inhibitor-induced a oligomerization gave us an impetus to study the kinetics of the dATP-driven hexamerization as a starting point. hRNR homo-oligomerization is an area of great pharmaceutical interest, [9] [10] [11] [12] and its relevance has been biochemically proven with both the isolated enzyme [8-11, 13, 14] and the functional hRNR-a ectopically expressed in cells. [12] However, the mechanism and kinetics of the individual steps in the pathway remain unmapped in RNR from any species. The results of discontinuous inhibition assays and electron microscopy studies have inferred only an upper limit (3-4 min). [11, 12] In a FRET-based mixing assay using a fluorescence stoppedflow device, we first tested the conditions that permitted only dimerization-namely, dATP-induced D57N-a dimerization. [10, 26] Total fluorescence at wavelengths of > 505 nm was monitored after the rapid mixing of a 1:5 solution of F-:T-D57N-a from one syringe and 200 mm dATP from another ( Figure S7 A) . The process was surprisingly slow, requiring measurements longer than 180 s. The hyperbolic trace fit a second-order dimerization rate law:
where I(t), I 0 and I 1 designate the fluorescence intensity at time t, time zero, and infinite time, respectively, and (Figure 4 B) . 2) Provided that dATP was present in saturating concentrations, changing dATP concentration had little or no effect on the rate (Figure S7 B) , implying that dATP binding was rapid under these conditions. 3) A plot of the rate of total fluorescence intensity drop [dI(t)/dt] versus [I(t)] 2 was also linear, further confirming the second-order nature of the kinetic process (Figure 4 C) . The data revealed that D57N-a dimerization induced by dATP binding at the S site occurs with a bimolecular rate constant of (5.8 AE 0.2) 10 4 m À1 s À1 . Although in our hands, D57N-a was observed to be a dimer at 100 mm dATP, [11, 12] high dATP concentrations have been implicated to induce further oligomerization of the mutant. [13] The bimolecular rate constant derived above was thus unambguiously verified by replicating the experiments at low dATP concentrations in which the mutant was undisputedly a dimer ( Figure S8 ). The dimerization rate constants were found to be largely unal- We also probed whether the a dimerization rate was influenced by the identity of the nucleotide effector. We thus opted to exploit an dGTP allosteric effector that binds exclusively at the S site and induces wt-a dimerization. [6, [8] [9] [10] [11] We first confirmed under steady-state conditions that the addition of saturating amounts of dGTP (0.1 mm) to a 1:5 mixture of F:Twt-a promoted a 30-35 % percentage drop in F-a intensity, a value within the range observed for dATP-induced D57N-a dimerization ( Figure S9 A) . The subsequent stopped-flow monitoring of dGTP-induced wt-a dimerization revealed a kinetic trace that best fit the dimerization rate equation [Eq. (1)]. The analysis provided a second-order rate constant of (7.7 AE 0.6) 10 4 m À1 s À1 (Figure S9 B) . Although substrate specificity was conferred by specific effector binding at the S site-dGTP binding selecting ADP substrate and dATP binding selecting UDP substrate [6, [8] [9] [10] -our data suggest that the two different effectors induced a dimerization at nearly identical rates.
We then probed a hexamerization with stopped-flow mixing of the wt protein and the feedback inhibitor dATP. The altered oligomeric state of mammalian a in the presence of the natural inhibitor dATP has been investigated by using various biophysical methods. [8] [9] [10] [11] [12] [13] [14] Gel filtration, [10, 11, 14] dynamic light scattering [10, 13] and gas-phase electrophoretic molecular mobility [14] analyses have collectively established that dATP binding to the A site drives mammalian RNR-a hexamerization. X-ray crystallography and electron microscopy data from 6.6 dATPbound Saccharomyces cerevisiae RNR-a hexamers [10] and ClF nucleotides-induced hRNR hexamers, [12] respectively, have also provided structural insights into the inhibited complexes that adopt the trimer-of-dimers assembly. In the present study, we sought to construct the missing kinetic model of dATP-assisted eukaryotic RNR-a hexamerization exemplified by the human enzyme.
D57N-a was replaced with wt-a under the stopped-flow conditions described above (Figure 4 D) . The resulting kinetic trace was identical to that obtained from the stopped-flow mixing of D57N-a and dATP, except in the early period, which featured an additional fast phase. Consistent with this observation, initial fitting of this trace to the dimerization equation showed a deviation from the fit within the < 10 s period. Conversion of this kinetic trace to a plot of the rate of total fluorescence intensity drop (Figure 4 C) revealed that, unlike the trace obtained for dATP-induced D57N-a dimerization, that of the dATP-induced wt-a hexamerization deviated clearly from linearity. The overall time course of dATP-induced wt-a hexamerization was best fit to a two-step kinetic model by using the Berkeley Madonna program (v 8.3.18) [Figures 4 D and 5,  Eqs. (2.1)-(2.4) ]. The fast phase fit well to a monoexponential rate law with a rate constant of 1.3 AE 0.2 s
À1
. Interestingly, the fitted second rate constant belonging to the slow phase of the FRET change in wt-a, (6.9 AE 0.6) 10 4 m À1 s
, was very close to the dimerization rate constant for D57N-a determined above:
. This unexpected finding suggested that the slow phase is associated with dimerization.
We used Equations (2.1)-(2.4) to model the observed kinetic trace as a two-step sequence: a!a*!(a*) 2 , in which a* was postulated to be a with an altered conformation. Steps subsequent to the rate-determining dimerization did not affect the kinetic trace or the derivation of Equation (2.4) (see the Supporting Information for more details):
ð2:3Þ
IðtÞ ¼ I 0 ÀU ½a*ÀV ½ða*Þ 2 ð 2:4Þ
In Equations (2.1)-(2.4), a* represents an intermediate formed during the fast phase, (a*) 2 is a dimer that can undergo further oligomerization at a rate(s) faster than that of (a*) 2 formation, k 1 and k 2 are the rate constants of the two steps, I(t) and I 0 designate the measured fluorescence intensity at time t and time zero, respectively, and U and V are constants. Figure 5 A and B shows a kinetic simulation of this model using the Berkeley Madonna software. To test the hypothesis that a!a* conversion was associated with conformational transition, we evaluated the effects of various protein concentrations (Figure 5 C) . As expected, a large part of each of the resultant traces representing the rate-determining dimerization step was affected by protein concentration. Extraction of the rate constants (Table S2 ) by fitting the averaged traces at each a concentration to Equations (2.1)-(2.4) revealed that the fast phase preceding dimerization was a unimolecular process independent of protein concentration ( Figure S10 ). By contrast, excluding the initial 10 s period from each trace and approximating the remaining part to dimerization [Eq. (1)] showed that the apparent rate constants for the slow step changed linearly as a function of a concentration ( Figure S10 ).
These data unexpectedly revealed that a dimerization is the rate-determining step in dATP-promoted wt-a hexamerization, but subsequent faster step(s) were not revealed. The fast step relating to the proposed conformationally altered a* was notably absent in the wt-a dimerization triggered by dGTP binding at the S site, as well as in D57N-a dimerization in which dATP only associates with the S site under the given conditions. We thus posit that the rapid conformational transition of a to a* (< 10 s), unique to wt-a, is linked to dATP-binding at the A site, effectively giving rise to a dimer primed specifically to proceed ultimately to formation of the hexameric (a 6 ) state. As this priming step was absent in D57N-a with dATP and in wt-a with dGTP bound at the S site (Figure 4 A-C, 5 C inset, S7-9), dATP binding at the A site on wt-a likely enables allosteric adjustments through conformational transitioning at an early step that precedes dimerization.
The rate-determining nature of the dimerization limited our ability to obtain a readout of the kinetics of the remaining steps representing the a 2 !a 6 transition. Because termolecular events in which the three a 2 dimers simultaneously assemble into a hexamer are statistically improbable, the a 4 state is likely a transient intermediate along this pathway. As the rate constants of dGTP-induced wt-a dimerization and dATP-induced D57N-a dimerization are similar, the dGTP-bound (wt-a) 2 dimer is considered a reasonable dimeric precursor with a vacant A site to accept dATP, thereby proceeding along the a 2 !a 6 trajectory. Thus to approximate the kinetics of the a 2 !a 6 oligomeric transition, we performed stopped-flow mixing of one syringe containing wt-a pre-incubated with 0.1 mm dGTP and another containing 200 mm dATP (Figure 6 A) . Although the overall trace did not fit to simple rate laws, the initial period (5 0 s) fit well to the second-order dimerization equation [Eq. (1)] (Figure 6 B) . This initial period presumably reports the . The fact that the rate constant for a 2 !a 6 conversion was an order of magnitude faster than that for the rate-determining dimerization (~6 10 4 m À1 s À1 ) was in line with our expectations. These observations further reinforced the previous findings that the new fluorescence platform can differentiate the initial dimerization event from the subsequent formation of higher-order a oligomers. Because of the known stability of the a 2 and a 6 states in the presence of appropriate effectors under saturating concentrations, [8] [9] [10] [11] [12] [13] [14] we were interested to probe the dissociation rate under the same experimental conditions, in addition to the rate of association. As an initial step, the propensity of dimer decomplexation was examined by using dATP-bound D57N-a dimers. Addition of a large excess of unlabeled D57N-a dimer to a sample containing labeled dimer resulted in a slow (~1 h) recovery of donor intensity at 520 nm (Figure 6 C) . A monoexponential fit to the data gave a first-order rate constant of (1.1 AE 0.2) 10 À3 s À1 for the subunit exchange process, which is equivalent to the dimer dissociation rate constant [28] in the presence of saturating concentrations of dATP. From a 2 association and dissociation events, the dimer-monomer equilibrium constant in the presence of saturating concentrations of dATP was calculated to be 18 nm. In the absence of any nucleotide, the equilibrium constant for the dimer-monomer transition has been reported to be 170 mm. [29] 
Conclusions
We have developed a simple readout that can directly report hRNR-a oligomerization events with high sensitivity. The presteady-state kinetic analyses with this newly developed platform revealed that: 1) hRNR oligomerization is a slow process; 2) dimerization is the unexpected rate-limiting step along the dATP-induced hexamerization-coupled inhibition pathway (Figure 6 D) ; 3) the rates of dimerization in response to nucleotide binding at the allosteric specificity (S) site are similar for dGTP and dATP, likely suggesting that substrate selection is not governed by kinetics but through the binding equilibrium; 4) the dissociation of dimer is very slow, implying that the complex, once formed, is tight in the presence of saturating concentrations of dATP; and 5) kinetics of the subsequent steps beyond the rate-determining dimerization were estimated to be an order of magnitude faster. In this model, the reverse process is considered negligible in the presence of saturating concentrations of dATP.
dATP is the only endogenous ligand capable of downregulating RNR activity. [5, 6, 8, 9, 30] Thus, feedback regulation is essential in maintaining dNTP pools at appropriate levels and sustaining DNA replication fidelity. [9, 30] Our initial data provide a starting point for understanding oligomeric regulatory kinetics in response to an important feedback inhibitor. Analogous measurements of ClFD(T)P-induced a hexamerization will be the subjects of future studies. Our fluorimetric platform also paves the way toward rapid identification of non-nucleotidebased small molecules that can bind and promote self-assembly of a. Such molecules could have the potential to inhibit hRNR.
Experimental Section
See the Supporting Information (Tables S1-S2 and Figures S1-S11) for complete experimental methods. À3 s À1 for a 2 !a. Dimerization was the rate-determining step (R.D.S) and was estimated to be one order of magnitude slower than subsequent oligomerization steps. a* is the proposed conformationally altered transient state of a that can ultimately undergo a hexamerization process, as described in the text. The tetrameric state is proposed as a transient intermediate because a 2 trimerization directly to a 6 in a single step is considered to be an unlikely event. Ribbon depictions for a 2 and a 6 are based on the known crystal structures of hRNR-a (2WGH) and yeast RNR-a (3PAW), respectively. Each a monomer is shown in dark and light gray, and the N-terminal domain housing the A site is shown in black. See the Table of Contents for a color figure.
